The vaccine's near eradication of measles starved drug development for decades. With immunity walls cracking, researchers are racing to build a backup plan that barely exists.
The measles vaccine worked so well that the world's scientists stopped building a backup. Now the backup is urgently needed, and the pipeline for it is thin, slow, and structurally disadvantaged by the very success that made it unnecessary.
For more than six decades, measles control meant the MMR vaccine, not therapeutics. Two doses of that shot are roughly 97% effective at preventing infection, and population coverage above about 95% blocks the chains of transmission that keep the virus spreading. With that tool working, drugmakers had little reason to spend the years and money it takes to develop a measles antiviral. There simply wasn't a market.
"We haven't had the need to develop measles antivirals," said Ruth Lynfield, an epidemiologist with the Minnesota Department of Health, at a May 27 news briefing. "It hasn't been a priority. I do think we need to invest in that now."
The wall that vaccine success built is now showing cracks. In the United States, 2,030 measles cases had been reported as of June 4, on pace to surpass totals last seen in 1991, before sustained elimination. That trajectory, driven by falling childhood vaccination in some regions and outbreaks seeded by international travel, has turned a back-burner research question into a front-burner one. Clinicians still have no approved drug to treat the disease. Care for a measles infection today means managing fever, cough, and the hallmark head-to-feet blotchy rash while the immune system does the work.
Why is a measles antiviral harder than a pill for, say, influenza or hepatitis C? The virus replicates quickly and is then largely cleared by the immune response, which leaves a narrow window in which an antiviral can do meaningful work. The candidate patient population is small outside outbreaks, which makes running the large, placebo-controlled trials regulators expect difficult. And unlike a chronic virus, measles gives a drug company a short treatment course to sell, on a small market, for a disease most clinicians in wealthy countries thought they had already beaten. Funding agencies followed the same logic. For decades, the dollars went into vaccine delivery.
The handful of groups now trying to change that math include academic virologists screening existing antivirals for activity against measles and a small biotech effort that has begun a clinical trial of a candidate therapy. None of these programs are close to approval, and the timeline from a first-in-human study to a widely available drug typically runs years. Even an effective therapy would not replace vaccination. Two doses of MMR still prevent infection more reliably than any drug could treat it. A treatment, if one arrives, would serve a narrower role: shielding infants under one year old, who are too young for the vaccine, immunocompromised patients who cannot mount a strong response to the live attenuated shot, and giving clinicians a tool to blunt severity in active outbreak settings.
That last function is the most pressing right now. Public-health authorities in the United States and Europe are responding to outbreaks in undervaccinated communities with the same playbook they have used for years: isolate cases, trace contacts, and vaccinate the unprotected. The strategy works when coverage is high. It works less well where it is not, and the harder the response gets, the louder the case becomes for a therapeutic option, even an imperfect one.
Lynfield's warning, in the same briefing, was about the priority of that investment, not its timeline. Building a credible measles antiviral pipeline means years of basic virology, clinical trial design for an acute contagious disease, and the kind of sustained funding that vaccine success once made politically easy to defer. Vaccination remains the primary, most effective defense. The search for a plan B is what happens when the world realizes that plan A, however good, is no longer being used.